![]() |
| Wesley Burks, MD, and Edwin Kim, MD Photo Credit: Courtesy UNC School of Medicine |
The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows superior results in desensitizing children to peanuts. Results were recently published in the New England Journal of Medicine.
Peanut allergy affects approximately two percent of children in the United States, Canada, and other westernized countries, with a rapidly rising prevalence over the past 20 years. Currently there are no FDA approved treatment options for peanut-allergic children under the age of 4 years, but further research into the safety, efficacy, and tolerability of epicutaneous immunotherapy (EPIT) could play a significant role in novel options for immunotherapy. The EPITOPE trial, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, evaluating the safety profile of Viaskin, a novel form of EPIT, among peanut-allergic toddlers shows that after 12 months of treatment in children aged 1-3 years, the treatment was found to be statistically superior to placebo in desensitizing participants to peanuts, increasing the peanut dose triggering allergic symptoms. Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine is also a contributing author to the paper.




.jpg)

.jpg)
.jpg)

